Clonazepam is NOT Recommended for Dementia
Clonazepam and other benzodiazepines should not be routinely used for treating behavioral and psychological symptoms of dementia (BPSD), as they lack evidence of efficacy and carry significant risks including cognitive impairment, falls, respiratory depression, paradoxical agitation, and dependence. 1, 2, 3
Why Benzodiazepines Are Problematic in Dementia
The FDA label for clonazepam explicitly warns of paradoxical reactions including agitation, irritability, aggression, anxiety, and hallucinations—the very symptoms clinicians might be trying to treat in dementia patients—and notes these reactions are more likely in the elderly 2. Additionally, clonazepam causes:
- Cognitive impairment and interference with mental alertness 2
- Respiratory depression, particularly dangerous in elderly patients 2
- Physical dependence with potentially life-threatening withdrawal reactions 2
- Increased risk of falls (a major concern in dementia patients)
- Hypersalivation and difficulty handling secretions 2
What the Evidence Shows
A systematic review of randomized controlled trials found no significant efficacy advantage of benzodiazepines over other treatments for BPSD, with high dropout rates (approximately one-third of patients in multiple studies) 3. The authors concluded that available data do not support routine use of benzodiazepines for BPSD 3.
More recent guidelines from 2025 do not recommend benzodiazepines as a primary treatment option for BPSD, instead focusing on antipsychotics (like risperidone for aggression/psychosis), antidepressants (citalopram for agitation), and cognitive enhancers 4.
First-Line Approach: Non-Pharmacologic Strategies
Multiple expert guidelines recommend non-pharmacologic interventions as first-line treatment for BPSD, except in emergency situations involving imminent danger 1. These strategies conceptualize behaviors as stemming from unmet needs and environmental factors. Only when non-pharmacologic approaches fail and safety is compromised should pharmacologic options be considered—and even then, benzodiazepines are not the preferred choice 1.
When Might Clonazepam Be Considered?
The evidence suggests benzodiazepines might only be used in very limited circumstances 3:
- When other psychotropic medications are contraindicated or unsafe
- Significant medication allergies preclude standard treatments
- Severe tolerability issues with preferred medication classes
Even in these rare situations, use the lowest effective dose for the shortest duration possible, with close monitoring for paradoxical reactions, cognitive worsening, and falls 2.
Critical Caveat About Existing Users
If a dementia patient is already taking clonazepam chronically, do not abruptly discontinue it—this can precipitate life-threatening withdrawal seizures 2. Instead, implement a gradual taper (reduce dose by 50% every 4 weeks until reaching the starting dose, then discontinue after another 4 weeks) 5. However, the Canadian guidelines note that cholinesterase inhibitors should not be discontinued in patients with active psychosis, agitation, or aggression until symptoms stabilize 5—this same caution applies to avoiding destabilization during benzodiazepine withdrawal.
Bottom Line Algorithm
- First: Implement non-pharmacologic interventions for BPSD
- If pharmacotherapy needed: Use evidence-based options (risperidone for aggression/psychosis, citalopram for agitation, cholinesterase inhibitors)
- Avoid clonazepam except in rare cases where all other options are contraindicated
- If already prescribed: Plan gradual deprescription with close monitoring
- Never use for chronic management of dementia symptoms
The limited case reports showing benefit 6, 7 are vastly outweighed by the safety concerns, lack of systematic evidence, and availability of better alternatives.